d e b g b q ? k d b ? j ? d h f ? g > : p b b i h > b ... · g _ w n n _ d l b \ g h k l v b...

22
ɄɅɂɇɂɑȿɋɄɂȿ ɊȿɄɈɆȿɇȾȺɐɂɂ ɉɈ ȾɂȺȽɇɈɋɌɂɄȿ ɂ Ʌȿɑȿɇɂɘ ȼɁɊɈɋɅɕɏ ȻɈɅɖɇɕɏ əɁȼȿɇɇɕɆ ɄɈɅɂɌɈɆ 2013 ɝ

Upload: others

Post on 19-Apr-2020

17 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

2013

Page 2: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

2

«», « »

:

1.2.3.4.5.6.7.8.9.10.11.12.13.14.15.16.17.18.19.20.21.22.23.24.

:

Page 3: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

3

...................................................................................................................................................................... 41. .......................................................................................................................................................................... 4

1.1 .............................................................................................................................. 51.2 .............................................................................................................. 51.3 -10.............................................................................................................................................................. 5

2. ............................................................................. 52.1 .............................................................................................................................................................. 52.2 .................................................................................................................................................. 62.3 ...................................................................................................................................... 7

3. ...................................................................................................................... 73.1 ............................................................................................ 73.2 ....................................................................................................................................... 83.3 ............................................................................................................................. 9

4. ......................................................................................... 104.1 ............................................................................................................................................... 104.2 . ..................................................................................................................................................................... 104.3 . . ..................................................................................... 114.4. . . ..................................................................... 114.5. . . ................................................................................. 114.5.1 12

4.6 ........................................................................................................... 135. ............................................................................................ 13

5.1 .................................................................................................. 135.1.1. 135.1.2. 135.1.3. 14

5.2 ............................................................................................................. 155.3 .......................................................................................................... 155.3.1. , 155.3.2. - 165.3.3. ,, 16

5.4. .................................. 165.4.1. 165.4.2. 165.4.3. 17

5.5 ....................................................... 175.5.1. 175.5.2. 175.5.3. 17

5.6............................................................................................................................... 17

5.6.1. 185.6.2. 185.6.3. 18

6. ........................................................................................................................................................................... 19

Page 4: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

4

– 5- – 5-6- – 6-

- –

– – -

– –

– –

– –

– –

– –

1. ( ), ( )

( ), .,

, , , .

, , , , 12.

( ) – , . ,

», , .

21 268 100 . 5-20 100 ,

6 40 )3.

– 20-30 , , , 4.

, . .

, .

: , , .

( 1).

1.5

1 1b

« » ( )

« »

Page 5: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

5

,

>2 ( )

2b « » ; .

<80% , )

« »;

3b « »3b

»

« -»

4

« »

(

» )5

, «

»

,

« »

1 2 3

1 4 2 3

D 4

1.1 ,

, , .

. .

« » 17 2012 . .

, , ,.

1.2

, ,

.1.3 -10

51

2. 6

2.1 – ,

. ( ),

, () .

Page 6: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

6

( , ), .

, 3 .

, .

( 5, D)7

8. :1. – ,

3 ;2. –

;3. – .

2.2 , ,

( 1b, ), ( 2, ).9

( 2.2.1),

( 5, D). 2.2.1. 10.

( ),

):

1. ( 6 ):. .. .

2. ( 6-).

3. ( 6- ):. (1 ).. (2 ).

: , , , ,

. ( ) ( 1b, ), Truelove-Witts,

, , ( ;DAI), , . ,

( 2.2.2 2.2.3).

2.2.2. Truelove-Witts11.

<4 4, : 6, :90 >90 37,5° >37,5°105 <105 30 >30

2.2.3. ( ).0 1 2 3

1–2/ 3–4/ 5/

Page 7: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

7

(1

Schroeder) (2

Schroeder)

(3 Schroeder)

( 4 ) 6 .

Schroeder 2.2.4. . 2.2.4. ( Schroeder)12.

0 1 ()

2 ()

3 ()

, .

.

, ,

,).

,.

, . :

1. :. – , ,

2 , 7 ;. –

, 1 , 4 .2. :

. , 10-15 3 ;

. 3 .

2.3 , ,

, , ( . « »).

:1. , , , ».2. , , , .

. ( )».3. , , , .

. ».

3. 13

3.1

, , . , , ,

.

(,

, , .) )

(

)

Page 8: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

8

: ( ), ; ,

.

)

( ,, )

14

, :

, :

:

)

,)

) ( ,

, ,)

,

, )

( )

, ,

, , . ,

5.2.2 « » 5.2.3 «»

3.2 .

, ( 5, D). :

, , , ,, ( ,

( )), ( 5, D);

, , ,, ,

, ( ), ), ( ,

.) ( 5, D);, , ( 5, D);

( ) ( 5, D):o ;

:o ,

;o – (

); ( 1b, B):

o ;o ;o ( 7-10 ) – (

) ( 3 , ); . 5.1.3 «»;

o 4 ,

1b, B);

Page 9: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

9

, , ( 3,);

( 2b, B):o ;o ;o Cl.difficile

, , 1516. 90% 4 1718;

o,

19,20 ( 2b, B);:

o , ;o ;o ;o ( : , , ,

);o ;

.

:;

;;

;;

;;

- .

:, ( , .); ( ,

); ( , .); ( , .);

( )., ,

. , ,

, . ( ),

( 2b, ). ( 5, D).

( ,, , , « »,

), « » , , ,

, .

.

3.3 ( ) –

. .

, . , ,, , .

Page 10: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

10

, .

, :;

:o ;o ;o ;o ;o ;

, ; ( ,

Cl.difficile)21;;

;;

; ( )22;

.

4. 23

4.1 ,

, .,

, , ,,

24,25. (

12 )26, , , , –

. ( ),

( ) ., .

27.

4.2 ..

(1 – 2 ) (1-2 ).28 2 ( 1b, )29.

6-8 . (

10 1-2 ) ( 5, D) 30. – ( ) 1-2 3

( 2 ) ( 1b, )31. 3 – 4

( 1b, B)32. ( 0,75) ( ) 2 6- (6- ) 1,5 ( 4, C).

( 10 1-2 ) ., ,

2 6- 1,5 2 . ( )

, 1 ( , ) ( 5,

D)., ) 1-2 3

1,5-2 – 2 ( 1b, ). ,

Page 11: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

11

2 ( 6- 1,5 ) ( 6- ) 2 ( 5, D).

4.3 . . 3 . ( 4 .)

2-4 . ( ). ( , )33,34,35. 2 . 6-8

. 5- ( 125 1-2 ) ( ,

). 5- , , ( . ).

1,536. 2 2 ( . « »)

( 1b, ). (3 ) ( 1b, ).

4.4. . . 4-5 .

2-4 . ( ) 37 ( , ). 2 . 6-8 .

1,5-2 . + 2 2 ( 1b, )38. 3 .

( 1b, )39. 5- , 1

2 6- 1,5 ( 1b, C). 2 . 6- 1,5

2 ( 1a, )40. 4

( 5 0, 2, 6 ) 2 6- 1,5 ( 1a, ). ( 6- )

8 ( 1b, ) 1 .41

, , - ( 5, D).

4.5. . ., 5 ,

90 , 37,8° , 105 ,

( 5, D).:

: 2 ; 2-4 125 ;

: , ();

( 80 , – , - );

, ;.

42; – ( 5, D):

o 1 - 1,5 + ( , ) 10-14 ;o 2 - 7-10 43,44.

7 .

7 : 1 0,8 5-10

4-8 ( 5-7

Page 12: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

12

50 .) ( 2b, B). , 12 . 30-40

3 . 1,5 – 2 2 .

3 ( 1b, ). 7 « »,

: 5 ( 0,

2 6 ) ( 1a, )45,46

2-4 7 ( 1a, )47,48.

8 1 ( 1b, ) 2 ( 6- 1,5 ) ( 2a, B)49,50.

7 2 ( )

12 . 3 .

2 2 ( 2b, )51. 2- 7-

.

4.5.1

. , , ,

, , 52.

, :

>12 2 55%53;

3 8 3 8 45 , 85% ( .

»)54; 3 « » : 0,14 -. 8 75%55;

5-9 , 40% 5

56; (

« ») 86-93%57,58. 25%

80%, . ,, , ,

:

59, 60, 61, 95 10

62.,

50.

78% 63.

Page 13: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

13

« » .

4.6 .:

– ; 12 ;

, D, ;

.:

– , , –

, )64; (

); (

).65

:• : , 2

20 2 , ;• 50 ;• : , ,

, .,

, . :

• HBV;• ;• .

26 .

5. 5.1

(, ) (

), ( , , ), .

5.1.1. ( . 2.2):

( , 6- ) 40-55% 66,67, 43-80%

68,69. ,

. «4.5.1. ».

5.1.2. , , :, 100

( , )

800 .

Page 14: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

14

, , , , .

. ( ),

6 . , ,

( . « ») .

, , ( , ).

o;

o , ( ) , :

, 2 , (), 1,5 .

( ) ., 50%

. ( , R- ) .

5.1.3. ,

. :

: 2% 10- , 8% - 20-18% - 30- 70;

, 71;

: , ;

72;;

. ,

73., 6-8

. , , . , ,

, ,

. , 6-8 ( . 5.1.3)

5.1.3. ( 6-8)

( /)

– 0-2 – 3-4

1-2 , – 3-4

, , , .

:1. 4 10 (

). ;

2. –, .

Page 15: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

15

:, ( .

), . .

( ): ,

1 . (

) , .

, , ,

, .

5.2

, 10%-30% ,

.7475 1980-, . 20

– ( ) 76,77.

78: 4 8 79,80,81, 700 ( 200

).

5.2.

, 2 : , 3 :1.

1.,

,

2.

1.

),

;2. ,

3.

(

)

5.3 ,

, , ,

3,5-10% 82,83,84.5.3.1. ,

65 , 85.

, , ,86. , ,

87,88. , .

Page 16: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

16

30-70%89,90,91,92,93

( 3b, ), , . , ,

.

( ). 10% ,

, ( ) , ( ).

, ,

.

.5.3.2. -

( ) , ( 4, ), 20

6 ( 4, ). ,, , ,

.

94,95,96, , 97,98.

5.3.3. 99,100,101

. , .

102,103 ( . 5.1.3»).

5.4.

, ( ,

104) ( 4, ).5.4.1.

, ( 4, ).

( . « ») ( ).

. , .

.,

.,

105, , .

5.4.2. ( 2 )

( ) 106.

2 ( 4, ). . ,

,

Page 17: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

17

( 4, ). ( 3b, ).

5.4.3. 12-18

, (« »)107,108,

. , (« »).

, (),

). , ,

( ) 2.

5.5 5.5.1.

20 6 109,110. 111,

112,113, 114.5.5.2.

(, . ),

.

, 2 ( , , ).

.

. (ECCO)115,

.,

(2 ) , 20

. .5.5.3.

. , .

( ) ( ) .

– . , (

, , , , , ,, , .)

. - ,

.

5.6

. 15 50% 10

Page 18: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

18

116,117,118. ,

( , 119,120).

5.6.1. ,

( , B). , ( )

3b, D)., ,

, ( ) . .

, , , ).

, , .

, , .

. , ( 5, D). ,

, , , .

, , . .

, .

, .

, , . –

, .

( ), , ( ) , , Clostridium difficile-

. ,.

5.6.2. , , ( ),

, . 14- (15-20 )

(1000 ). .

- (2000 ), , , , .

(9 ) 8 .

.5.6.3.

,. « »

500 2 . ( ) 121 ,

. ,,

.

, , , , .

Page 19: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

19

6. 15%,

. 5 , 10 - 20% .

4-9% (- 50%), 1%.

( ) , ,

.

1 . / . . , . . , 2008. – 754 c.2 ., . . , . 20083 Marchal J, Hilsden R. Environment and epidemiology of inflammatory bowel disease // in Inflammatory bowel disease. Ed. Satsangi J,Sutherland L – Churchill-Livingstone. – 2003. – 17-284 Irvine EJ, Farrokhyar F, Swarbick ET. Z critical review of epidemiological studies in inflammatory bowel disease. Scand. J. Gastroenterol.2001. 36(1): 2-155 OCEBM Levels of Evidence Working Group. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine.6 Dignass A, et al, Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions anddiagnosis, Journal of Crohn's and Colitis (2012)7 Travis SP, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol 2010;30:17–20.8 D'Haens G, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.Gastroenterology 2007;132:763–869 Katsanos KH, Vermeire S, Christodoulou DK, Riis L, Wolters F, Odes S, et al. Dysplasia and cancer in inflammatory bowel disease 10 yearsafter diagnosis: results of a population-based European collaborative follow-up study. Digestion 2007;75: 113–21.10 Silverberg MS, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of aworking party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5–36.11 Truelove SC et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041–8.12 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. Arandomized study. N Engl J Med 1987;317:1625–9.13 ., ., . .. - .

. 2011. 4-2. . 209-221.14 ., . . . 2011. 15. . 44-4915 Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. ClinGastroenterol Hepatol 2007; 5: 345-35116 Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. ClinGastroenterol Hepatol. 2007; 5: 339-34417 Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1432-4218 Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infectionamong hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443-5019 Mindenmark M, Larsson A. Rulling out IBD estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012; 45: 552-520 Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinalinflammation. Dig Liver Dis 2003;35:642–7.21 ., . : , , .

, , . 2007. . 17. 3. . 65-7122 ., ., . ., ., . V : ,

, . , , . 2006. .16, 6. . 56-6023 ., ., .

. . . . 2009. . 14, 3. . 29–3724 ., ., .. . . 2013. 2.

. 42-4625 . . , , , 2006.

16. 3. . 58-6226 Dignass A, et al, Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Currentmanagement, Journal of Crohn's and Colitis (2012).27 . (

). , 2006(2): .31-3328 Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trialsof active ulcerative colitis. Gastroenterology 2007;132:516–26.29 Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission inulcerative colitis. Cochrane Database Syst Rev 2010 [CD004115-CD004115].30 Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40: 775–81.

Page 20: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

20

31 Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twicedaily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011;56:513–2232 Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versuscombination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867–71.33 Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev2006:CD000543.34 Regueiro M, Loftus Jr EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: criticalevaluation of therapeutic trials. Inflamm Bowel Dis 2006;12:979–94.35 Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic reviewand meta-analysis. Am J Gastroenterol 2011;106:601–16.36 Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev GastroenterolDisord 2003;3:210–8.37 Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic reviewand meta-analysis. Am J Gastroenterol 2011;106:601–16.38 Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the reatment of active ulcerative colitis: a systematic review. Rev GastroenterolDisord 2003;3:210–8.39 Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev2006:CD000543.40 Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerativecolitis. Aliment Pharmacol Ther 2009;30:126–37.41 Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severeulcerative colitis. The UC SUCCESS trial. J Crohns Colitis 2011;5:13.42 Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, Abad-Lacruz A, Cabre E, Acero D, et al. Enteral versus parenteral nutrition asadjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993;88:227–3243 Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Abadir A, et al. Antibiotic therapy in inflammatory bowel disease: a systematic reviewand meta-analysis. Am J Gastroenterol 2011;106:661–73.44 Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, et al. Newly developed antibiotic combination therapy for ulcerativecolitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010;105:1820–9.45 Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severeulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.46 Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, et al. A retrospective analysis of the efficacy and safety of infliximab as rescuetherapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411–9.47 Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025–31.48 Sjoberg M, Walch A, Meshkat M, Gustavsson A, Jarnerot G, Vogelsang H, et al. Infliximab or cyclosporine as rescue therapy in hospitalizedpatients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis 2012; 18(2), p.212-8.49 Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, et al. Usefulness of co-treatment with immunomodulators in patientswith inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363–8.50 Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy forulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201–11.51 Chebli LA, LDdM Chaves, Pimentel FF, Guerra DM, RMdF Barros, Gaburri PD, et al. Azathioprine maintains long-term steroid-freeremission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010;16:613–9.52 Randall JSB, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk ofpostoperative complications. Br J Surg 2010;97: 404–953 Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut 1975;16:579–8454 Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut1996;38:905–1055 Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severeand moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831–556 Benazzato L, D'Inca R, Grigoletto F, Perissinotto E, Medici V, Angriman I, et al. Prognosis of severe attacks in ulcerative colitis: effect ofintensive medical treatment. Dig Liver Dis 2004;36:461–657 Almer S, Bodemar G, Franzen L, Lindstrom E, Nystrom P, Strom M. Use of air enema radiography to assess depth of ulceration during acuteattacks of ulcerative colitis. Lancet 1996;347: 1731–5.58 Carbonnel F, Lavergne A, Lemann M, Bitoun A, Valleur P, Hautefeuille P, et al. Colonoscopy of acute colitis. A safe and reliable tool forassessment of severity. Dig Dis Sci 1994;39: 1550–7.59 Ferrante M, Vermeire S, Katsanos KH. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007Feb;13(2):123-8.60 Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A. Open-label infliximab therapy in ulcerative colitis: a multicenter survey ofresults and predictors of response. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14.61 Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximabpharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010 May;48(5):297-308.62 Oussalah A, Evesque L, Laharie D, Roblin X. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors ofresponse, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010 Dec;105(12):2617-2563 . , . , . , . .

. , , , 2013. 3.64 American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis inthe United States. Am J Respir Crit Care Med, 2005. 172(9): p. 1169-227.65 Rahier, J.F., et al., European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections ininflammatory bowel disease. J Crohns Colitis, 2009. 3(2): p. 47-9166 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi PG. Randomised controlled trial of azathioprine and 5-aminosalicylic acidfor treatment of steroid dependent ulcerative colitis. Gut 2006;55:47–53

Page 21: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

21

67 Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severeulcerative colitis. The UC SUCCESS trial. J Crohns Colitis 2011;5:13.68 Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025–31.69 Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025–31.70 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–3571 Jess T, Loftus Jr EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal cancer in inflammatory bowel disease: apopulation-based study from olmsted county, Minnesota. Gastroenterology 2006;130:1039–4672 Bergeron V, Vienne A, Sokol H, Seksik P, Nion-Larmurier I, Ruskone-Fourmestraux A, et al. Risk factors for neoplasia in inflammatorybowel disease patients with pancolitis. Am J Gastroenterol 2010, [advance online publication, 15 June 2010]73 Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasiain ulcerative colitis. Gastroenterology 2004;126:451–974 . . , . : 2012. « », .460-522.75 Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis // Gut 1996;38:905—10.76 Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis2001;3:223–6.77 McLaughlin SD, Clark SK, Thomas-Gibson S, Tekkis P, Ciclitira PJ, Nicholls RJ. Guide to endoscopy of the ileo-anal pouch followingrestorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm BowelDis 2009;15:1256–63.78 Berndtsson I, Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis—a prospectivestudy. Colorectal Dis 2003;5:173–979 Marcello PW, Roberts PL, Schoetz Jr DJ, Coller JA, Murray JJ, Veidenheimer MC. Long-term results of the ileoanal pouch procedure. ArchSurg 1993;128:500–3 [discussion 503–4]80 Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis 1997;15:172–88.81 Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications andlong-term outcome in 1310 patients. Br J Surg 1998;85:800–3.82 Setti-Carraro P, Ritchie JK, Wilkinson KH, et al. The first 10 years’ experience of restorative proctocolectomy for ulcerative colitis. Gut.1994;35:1070–107583 Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–12784 Belliveau P, Trudel J, Vasilevsky CA, et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg. 1999;42:345–35285 Pinto RA, Canedo J, Murad-Regadas S, Regadas SF, Weiss EG, Wexner SD. Ileal pouch-anal anastomosis in elderly patients: is there adifference in morbidity compared with younger patients? Colorectal Dis 2011;13:177–8386 Church JM. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z JSurg 2000;70:906–787 Chapman JR, Larson DW, Wolff BG, Dozois EJ, Cima RR, Pemberton JH, et al. Ileal pouch-anal anastomosis: does age at the timeof surgeryaffect outcome? Arch Surg 2005;140:534–4088 Delaney CP, Dadvand B, Remzi FH, Church JM, Fazio VW. Functional outcome, quality of life, and complications after ileal pouch-analanastomosis in selected septuagenarians. Dis Colon Rectum 2002;45:890–4.89 Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg1999;86:493–5.90 Ording OK, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and aftersurgery compared with a population sample. Gastroenterology 2002;122:15–9.91 Gorgun E, Remzi FH, Goldberg JM, Thornton J, Bast J, Hull TL, et al. Fertility is reduced after restorative proctocolectomy with ileal pouchanal anastomosis: a study of 300 patients. Surgery 2004;136:795–803.92 Johnson P, Richard C, Ravid A, Spencer L, Pinto E, Hanna M, et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis.Dis Colon Rectum 2004;47:1119–26.93 Oresland T, Palmblad S, Ellstrom M, Berndtsson I, Crona N, Hulten L. Gynaecological and sexual function related to anatomical changes inthe female pelvis after restorative proctocolectomy. Int J Colorectal Dis 1994;9:77–81.94 Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of atertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003;197:379–8595 Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 2002;184:45–51.96 Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum 2005;48: 70–3.97 Holubar SD, Larson DW, Dozois EJ, Pattana-Arun J, Pemberton JH, Cima RR. Minimally invasive subtotal colectomy and ileal pouch-analanastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum 2009;52:187–92.98 Marceau C, Alves A, Ouaissi M, Bouhnik Y, Valleur P, Panis Y. Laparoscopic subtotal colectomy for acute or severe colitis complicatinginflammatory bowel disease: a case-matched study in 88 patients. Surgery 2007;141:64099 Annibali R, Oresland T, Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis ColonRectum 1994;37:321–9.100 Burns EM, Bottle A, Aylin P, Clark SK, Tekkis P, Darzi A, et al. Volume analysis of outcome following restorative proctocolectomy. Br JSurg 2011;98:408–17.101 Tekkis PP, Fazio VW, Lavery IC, Remzi FH, Senagore AJ, Wu JS, et al. Evaluation of the learning curve in ileal pouch-anal anastomosissurgery. Ann Surg 2005;241:262–8.102 Lepisto A, J. JH.. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg 2005;94:40–2103 Burns EM, Bottle A, Aylin P, Clark SK, Tekkis P, Darzi A, et al. Volume analysis of outcome following restorative proctocolectomy. Br JSurg 2011;98:408–17.104 Burns EM, Bottle A, Aylin P, Clark SK, Tekkis P, Darzi A, et al. Volume analysis of outcome following restorative proctocolectomy. Br JSurg 2011;98:408–17105 Edwards, C.M., B. George, and B.F. Warren, Diversion colitis: new light through old windows. Histopathology, 1999. 35(1): p. 86-7.

Page 22: D E B G B Q ? K D B ? J ? D H F ? G > : P B B I H > B ... · G _ w n n _ d l b \ g h k l v b e b g _ \ h a f h ` g h k l v i j h ^ h e ` _ g b y d h g k _ j \ Z l b \ g h c l _ j

22

106 Annibali R, Oresland T, Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis ColonRectum 1994;37:321–9107 Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological andhistochemical study of mucosal biopsy specimens. J Clin Pathol 1987;40:601–7.108 Setti Carraro PG, Talbot IC, Nicholls JR. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorativeproctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis 1998;13:103–7.109 Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications inpatients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1062–70.110 Lake JP, Firoozmand E, Kang JC, Vassiliu P, Chan LS, Vukasin P, et al. Effect of high-dose steroids on anastomotic complications afterproctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg 2004;8:547–51.111 Mahadevan U, Loftus Jr EV, TremaineWJ, Pemberton JH, Harmsen WS, Schleck CD, et al. Azathioprine or 6-mercaptopurine beforecolectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002;8:311–6.112 Pugliese D, Armuzzi A, Rizzo G, et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients withinflammatory bowel disease. Gut 2010;59(Suppl III):A13113 Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory boweldisease treated with immunomodulators. Br J Surg 2006;93:793–9114 Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoingabdominal surgery. Yang Z, Wu Q, Wang F, Wu K, Fan D. Aliment Pharmacol Ther. 2012 Nov;36(10):922-8. doi: 10.1111/apt.12060. Epub2012 Sep 24.115 Dignass, A., et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: currentmanagement. J Crohns Colitis, 2012. 6(10): p. 991-1030.116 Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complicationsand long-term outcome in 1310 patients. Br J Surg 1998;85:800–3.117 Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg2000;24:851–6118 Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, Lofberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence,cumulative risk, and risk factors. Dis Colon Rectum 1996;39:1012–8.119 Penna C, Tiret E, Kartheuser A, Hannoun L, Nordlinger B, Parc R. Function of ileal J pouch-anal anastomosis in patients with familialadenomatous polyposis. Br J Surg 1993;80:765–7120 Tjandra JJ, Fazio VW, Church JM, Oakley JR, Milsom JW, Lavery IC. Similar functional results after restorative proctocolectomy in patientswith familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg 1993;165:322–5121 Shen B, Achkar JP, Lashner BA. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-analanastomosis. Am J Gastroenterol. 2002 Apr;97(4):972-7.